Updated:
SFJ Pharmaceuticals
SFJ Pharmaceuticals is a pharmaceutical company based in Pleasanton, United States, established in 2008. It employs a new business model for clinical...
SFJ Pharmaceuticals
SFJ Pharmaceuticals is a pharmaceutical company based in Pleasanton, United States, established in 2008. It employs a new business model for clinical development and registration of pharmaceutical products. The company has secured $144.5 million in total funding.
General information
Firm type
Asset Manager
Year founded
2009
Location
Region
North America
Country
United States
City
Pleasanton
Corporate office
Pleasanton, CA, United States
Principals
Robert DeBenedetto
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at SFJ Pharmaceuticals?
Robert DeBenedetto founded the firm in 2009 and serves as its leader. SFJ is owned by Blackstone Life Sciences and Abingworth Ventures, which provide oversight as primary investors (per firm website).
How does SFJ Pharmaceuticals source proprietary deal flow?
SFJ originates deals through direct partnerships with biotech and pharma companies. The firm's website highlights collaborations with Eisai, Pfizer, Apellis, PhaseBio, and Nektar Therapeutics, suggesting a network-driven approach targeting clinical-stage assets (per firm website).
Is SFJ Pharmaceuticals structured as a single family office or does it operate more like a venture firm?
SFJ is not a family office. It is a hybrid asset manager and co-development firm, structured as a joint venture between Blackstone Life Sciences and Abingworth Ventures (per firm website).
Does SFJ Pharmaceuticals participate in fund commitments or only direct deals?
SFJ engages exclusively in direct co-development deals. The firm provides 100% of clinical trial funding for partnered assets, rather than investing in external funds (per firm website).
What investment stages does SFJ Pharmaceuticals typically target?
SFJ targets clinical-stage biopharmaceutical assets, focusing on Phase 2 and Phase 3 development. The firm also supports follow-on indications and ex-US regulatory approvals (per firm website).
Which sectors does SFJ Pharmaceuticals explicitly avoid?
SFJ focuses exclusively on pharmaceuticals and biotechnology. The firm does not publicly disclose any explicitly avoided sectors, but its portfolio concentrates on oncology and hematologic indications (per firm website).
How is SFJ Pharmaceuticals related to Blackstone and Abingworth?
SFJ is jointly owned by Blackstone Life Sciences (formerly Clarus Funds) and Abingworth Ventures. The two firms are its primary investors, and SFJ operates as a partnership under their umbrella (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: